Literature DB >> 3498446

Measurement of anti-DNA antibodies: a reappraisal using five different methods.

D A Isenberg, C Dudeney, W Williams, I Addison, S Charles, J Clarke, A Todd-Pokropek.   

Abstract

One hundred and thirty coded sera, 60 from patients with systemic lupus erythematosus (SLE) and 70 from patients with other autoimmune rheumatic diseases were tested for deoxyribonucleic acid (DNA) binding activity by five different types of assay. These were enzyme linked immunosorbent assay (ELISA) (distinguishing IgG and IgM anti-ssDNA and anti-dsDNA), Crithidia luciliae, a nitrocellulose filter assay, the Amersham kit, and another modified Farr assay, the radioimmunoassay (RIA) (UK). The Crithidia test was the most specific, none of the controls was positive, but the least sensitive (13% positive only). The RIA (UK) was the most sensitive (57% positive). In most of the assays 3-9% of the controls were positive. When the SLE sera were analysed according to disease activity the IgG anti-dsDNA ELISA, all three RIA values, and the Crithidia test values were raised in all the patients with severely active disease. Some patients with inactive disease, however, were positive in each of the tests. The best interassay correlations (r less than 0.49) were found between RIA (UK), and ss IgG and the Amersham kit; and between ds IgG and ss IgG. In the main, however, it was clear that different assays are dependent upon distinctive properties of DNA antibodies. It seems inevitable that most major rheumatology units will require more than one anti-DNA antibody assay.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498446      PMCID: PMC1002163          DOI: 10.1136/ard.46.6.448

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  32 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

3.  DNA antibody class, subclass, and complement fixation in systemic lupus erythematosus with and without nephritis.

Authors:  R D Sontheimer; J N Gilliam
Journal:  Clin Immunol Immunopathol       Date:  1978-08

4.  Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus.

Authors:  A J Swaak; L A Aarden; L W Statius van Eps; T E Feltkamp
Journal:  Arthritis Rheum       Date:  1979-03

5.  IgG antibodies to double-stranded DNA in systemic lupus erythematosus sera. Independent variation of complement fixing activity and total antibody content.

Authors:  A Beaulieu; F P Quismorio; G J Friou; B Vayuvegula; G Mirick
Journal:  Arthritis Rheum       Date:  1979-06

6.  A Millipore filter assay for antibodies to native DNA in sera of patients with systemic lupus erythematosus.

Authors:  B Ginsberg; H Keiser
Journal:  Arthritis Rheum       Date:  1973 Mar-Apr

7.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

8.  Antibodies to native DNA in systemic lupus erythematosus. A technique of rapid and quantitative determination.

Authors:  N M Kredich; J S Skyler; L J Foote
Journal:  Arch Intern Med       Date:  1973-05

9.  Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid.

Authors:  R T Wold; F E Young; E M Tan; R S Farr
Journal:  Science       Date:  1968-08-23       Impact factor: 47.728

10.  Immunochemical characteristics of antibodies to DNA in patients with active systemic lupus erythematosus.

Authors:  S P Ballou; I Kushner
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

View more
  33 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  Determination of anti-ds-DNA antibodies by three different methods: comparison of sensitivity, specificity and correlation with lupus activity index (LAI).

Authors:  A G Tzioufas; C Terzoglou; E D Stavropoulos; S Athanasiadou; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1990-06       Impact factor: 2.980

3.  Lack of specificity for antibodies to double stranded DNA found in four commercial kits.

Authors:  M Kadlubowski; M Jackson; P L Yap; G Neill
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

Review 4.  Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.

Authors:  Sean R Christensen; Mark J Shlomchik
Journal:  Semin Immunol       Date:  2007-02-02       Impact factor: 11.130

5.  Evaluation of five commercial kits to detect dsDNA antibodies.

Authors:  S A McMillan; A C Fay
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

6.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

7.  Effects of adjuvants for human use in systemic lupus erythematosus (SLE)-prone (New Zealand black/New Zealand white) F1 mice.

Authors:  E Favoino; E I Favia; L Digiglio; V Racanelli; Y Shoenfeld; F Perosa
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

8.  Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.

Authors:  D A Isenberg; C Dudeney; W Williams; A Todd-Pokropek; B D Stollar
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

9.  TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.

Authors:  Tanvi Arkatkar; Holly M Jacobs; Samuel W Du; Quan-Zhen Li; Kelly L Hudkins; Charles E Alpers; David J Rawlings; Shaun W Jackson
Journal:  Kidney Int       Date:  2018-06-12       Impact factor: 10.612

10.  Clinical evaluation of cobas core anti-dsDNA EIA quant.

Authors:  Concepción González; Paloma Guevara; Belén García-Berrocal; José Alejandro Navajo; José Manuel González-Buitrago
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.